Literature DB >> 3349791

Variability in aminoglycoside pharmacokinetics in critically ill surgical patients.

J F Dasta1, D K Armstrong.   

Abstract

The pharmacokinetics of the aminoglycosides were evaluated in 181 patients admitted to a surgical ICU. Pharmacokinetic parameters changed from 16% to 40% during therapy requiring multiple dosage adjustments and nearly nine drug levels per patient. Dosage adjustments resulted in peak and trough serum concentrations within the therapeutic range 71% and 74% of the time. Aminoglycoside half-life (T1/2) ranged from 1.1 to 69.3 h. Aminoglycoside volume of distribution also varied considerably with an average value of 0.36 L/kg. During therapy most patients gained weight (average 8.4 kg) which correlated with their corresponding fluid gain of 11.6 L. Pharmacokinetic parameters were variable even in patients with a normal serum creatinine. Less than 50% of these patients received the recommended daily dosages. This study suggests that the aminoglycoside volume of distribution in critically ill surgical patients differs from general hospital patients and pharmacokinetic parameters change considerably during therapy. We recommend obtaining timed serum aminoglycoside concentrations early in therapy and adjusting drug dosages as needed to maintain serum concentrations in the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349791     DOI: 10.1097/00003246-198804000-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  23 in total

1.  Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.

Authors:  Jason A Roberts; Jonathan Field; Adam Visser; Rosemary Whitbread; Mandy Tallot; Jeffrey Lipman; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

Authors:  K A Rodvold; R D Pryka; P G Kuehl; R A Blum; P Donahue
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 4.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

Review 5.  Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.

Authors:  Amélie Marsot; Romain Guilhaumou; Camille Riff; Olivier Blin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

Review 6.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 7.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered.

Authors:  Anne Veinstein; Nicolas Venisse; Julie Badin; Michel Pinsard; René Robert; Antoine Dupuis
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.

Authors:  Muhammad Jamshaid; Samia Yousuf; Nadeem Irfan Bukhari; Amir Ali Rizvi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.